Positive News SentimentPositive NewsNASDAQ:GYRE Gyre Therapeutics (GYRE) Stock Price, News & Analysis $5.95 -0.18 (-2.94%) Closing price 04:00 PM EasternExtended Trading$5.96 +0.01 (+0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gyre Therapeutics Stock (NASDAQ:GYRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gyre Therapeutics alerts:Sign Up Key Stats Today's Range$5.95▼$6.3450-Day Range$5.56▼$8.1052-Week Range$5.44▼$9.42Volume71,008 shsAverage Volume98,033 shsMarket Capitalization$577.32 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingHold Company Overview Gyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells. Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas. By leveraging its platform to validate novel targets and generate lead candidates, the company aims to address unmet medical needs where dysregulated lipid environments drive disease progression. Headquartered in South San Francisco, California, Gyre Therapeutics was founded in 2021 and completed its initial public offering on the Nasdaq Global Market under the ticker symbol GYRE in mid-2023. Operating primarily in the United States, the company collaborates with academic researchers and industry partners to advance its discovery efforts. Through its innovative focus on membrane biochemistry, Gyre seeks to build a diversified portfolio of first-in-class small-molecule therapies.AI Generated. May Contain Errors. Read More Gyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreGYRE MarketRank™: Gyre Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 531st out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingGyre Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialGyre Therapeutics has a consensus price target of $17.00, representing about 185.7% upside from its current price of $5.95.Amount of Analyst CoverageGyre Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Gyre Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gyre Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gyre Therapeutics is -66.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gyre Therapeutics is -66.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGyre Therapeutics has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gyre Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.90% of the float of Gyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverGyre Therapeutics has a short interest ratio ("days to cover") of 17.64, which indicates bearish sentiment.Change versus previous monthShort interest in Gyre Therapeutics has recently decreased by 0.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGyre Therapeutics does not currently pay a dividend.Dividend GrowthGyre Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentGyre Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Gyre Therapeutics this week, compared to 2 articles on an average week. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Gyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $219,580.00 in company stock.Percentage Held by Insiders9.50% of the stock of Gyre Therapeutics is held by insiders.Percentage Held by Institutions23.99% of the stock of Gyre Therapeutics is held by institutions.Read more about Gyre Therapeutics' insider trading history. Receive GYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GYRE Stock News HeadlinesGyre Therapeutics (NASDAQ:GYRE) COO Weiguo Ye Sells 9,400 SharesMay 23, 2026 | insidertrades.comGyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis TreatmentMay 12, 2026 | globenewswire.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 10 at 1:00 AM | Porter & Company (Ad)Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business UpdateMay 7, 2026 | globenewswire.comGyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyMay 4, 2026 | globenewswire.comGyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentMarch 17, 2026 | markets.businessinsider.comGyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentMarch 17, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE)March 15, 2026 | theglobeandmail.comSee More Headlines GYRE Stock Analysis - Frequently Asked Questions How have GYRE shares performed this year? Gyre Therapeutics' stock was trading at $7.06 at the beginning of 2026. Since then, GYRE shares have decreased by 15.7% and is now trading at $5.95. How were Gyre Therapeutics' earnings last quarter? Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted its quarterly earnings data on Thursday, March, 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.04. The firm had revenue of $37.20 million for the quarter, compared to analysts' expectations of $36.30 million. Gyre Therapeutics had a negative net margin of 5.44% and a positive trailing twelve-month return on equity of 3.13%. Who are Gyre Therapeutics' major shareholders? Gyre Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.04%), Dimensional Fund Advisors LP (0.03%) and Royal Bank of Canada (0.01%). Insiders that own company stock include Songjiang Ma, Ying Luo, Weiguo Ye and Nassim Usman. View institutional ownership trends. How do I buy shares of Gyre Therapeutics? Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gyre Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings3/12/2026Today6/10/2026AGM 20266/10/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 GYRE's financial health is in the Red zone, according to TradeSmith. GYRE has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GYRE Previous SymbolNASDAQ:GYRE CIK1124105 Webwww.catalystbiosciences.com Phone(619) 949-3681Fax336-480-2107Employees40Year FoundedN/APrice Target and Rating Average Price Target for Gyre Therapeutics$17.00 High Price Target$18.00 Low Price Target$16.00 Potential Upside/Downside+185.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.03 million Net Margins-5.44% Pretax Margin0.48% Return on Equity3.13% Return on Assets2.67% Debt Debt-to-Equity RatioN/A Current Ratio4.64 Quick Ratio4.06 Sales & Book Value Annual Sales$117.05 million Price / Sales4.93 Cash Flow$0.22 per share Price / Cash Flow27.59 Book Value$1.48 per share Price / Book4.02Miscellaneous Outstanding Shares97,028,000Free Float87,810,000Market Cap$577.32 million OptionableNo Data Beta1.90 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GYRE) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredOpenAI is preparing to go publicOpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...InvestorPlace | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredIn 30 days, you'll wish you'd read this emailA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
